৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Quantity:
Products
Payment
Delivery
Indications Anailiva tablet is indicated, in conjunction with diet and exercise, for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stage F2 to F3).
Stages of Liver Damage Pre-hepatic: Reversible fatty liver, restoration is possible.
Pharmacology Resmetirom is a partial agonist of the thyroid hormone receptor-beta (THR-β). It produces 93% of the maximum response compared to triiodothyronine (T3), with an EC50 of 0.2 μM. THR-β is the major form in the liver, and stimulation reduces intrahepatic triglycerides.
Dosage & Administration
For patients weighing <100 kg: 80 mg orally once daily.
For patients weighing >100 kg: 100 mg orally once daily. Resmetirom can be administered with or without food.
Drug Interactions
Strong/Moderate CYP2C8 inhibitors (e.g., Gemfibrozil, Clopidogrel) increase risk of adverse reactions.
OATP1B1 and OATP1B3 inhibitors (e.g., Cyclosporine) are not recommended.
Statins: Resmetirom increases plasma concentrations of atorvastatin, pravastatin, rosuvastatin, and simvastatin.
Rosuvastatin & Simvastatin: Max 20 mg/day.
Pravastatin & Atorvastatin: Max 40 mg/day.
Side Effects Diarrhea, nausea, vomiting, abdominal pain, dizziness, pruritus, constipation.
Pregnancy & Lactation
Pregnancy: No available data; risk of birth defects or miscarriage unknown.
Lactation: Unknown if present in human milk; benefits of breastfeeding should be weighed against maternal need for therapy.
Precautions & Warnings
Hepatotoxicity: Monitor liver function; discontinue if suspected.
Gallbladder-related events: Cholelithiasis, cholecystitis, pancreatitis observed. Interrupt treatment if suspected.
Use in Special Populations
Pediatric: Safety not established.
Geriatric: Higher incidence of adverse reactions in patients ≥65 years.
Renal impairment: Mild/moderate impairment – same dose as normal. Severe impairment – not studied.
Hepatic impairment: Avoid in decompensated cirrhosis; moderate/severe impairment increases risk.






Resmetirom is a novel oral medication classified as a thyroid hormone receptor-beta (THR-β) agonist.
It is specifically designed to treat nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (F2–F3 stages) in adults.
Resmetirom works by activating thyroid hormone receptors in the liver, which improves fat metabolism, reduces liver fat accumulation, and slows fibrosis progression.
It represents the first approved therapy for NASH with fibrosis, offering a targeted treatment option where previously only lifestyle changes and supportive care were available.
The drug is taken orally in tablet form and requires medical supervision with regular liver function monitoring.
First approved therapy for NASH: Resmetirom is the first oral drug specifically approved for nonalcoholic steatohepatitis (NASH) with liver fibrosis (F2–F3).
Reduces liver fat: Improves fat metabolism in the liver, lowering hepatic steatosis.
Slows fibrosis progression: Helps prevent worsening of liver scarring, reducing risk of cirrhosis.
Improves liver function: By reducing fat and fibrosis, it supports healthier liver performance.
Convenient oral dosing: Taken as a tablet, making treatment easier compared to invasive therapies.
Better patient outcomes: Provides a targeted option beyond lifestyle changes, improving quality of life for NASH patients.

